SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Annual Wellness Visit, Subsequent — Nelson Mandela — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientNelson Mandela
Date of birth1918-07-18
IdentifiersMRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718
Document date2001-06-09
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Subsequent annual wellness visit; no new complaints. [S]

History of Present Illness

Mr. Mandela is an 82-year-old man with unfavorable intermediate-risk prostate cancer, seven weeks after his first leuprolide injection, who is due to start radiotherapy in about six weeks. He returns for his subsequent annual wellness visit and completed the health risk assessment beforehand. He finished four weeks of bicalutamide without trouble. Since the injection he has had mild hot flashes, three or four a week, which wake him about once a week; his energy is a little lower in the afternoons, but he still walks every morning. His mood is good and he notices no change in memory or concentration. He has had no breast tenderness, chest pain, breathlessness, or leg swelling. Urinary symptoms are unchanged and mild. He takes vitamin D daily. He has had no falls, emergency visits, or hospital stays in the past year. [S]

ElementDetail
VisitSubsequent annual wellness visit
Safety eventsNo falls, emergency visits, or hospital stays in the past year
MedicinesLeuprolide 22.5 mg every twelve weeks (second dose due in five weeks); cholecalciferol 1000 units daily; bicalutamide finished four weeks ago
Active conditionsProstate cancer, unfavorable intermediate risk, on androgen deprivation before radiotherapy; low bone mass at the femoral neck
Functional statusIndependent in all activities and instrumental activities of daily living

Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]

DomainFinding
Self-rated healthGood
PsychosocialBusy with his foundation and visitors; close family and friends; no loneliness or low mood
TobaccoNever used tobacco
Alcohol and drugsNo alcohol (AUDIT-C 0); no other drug use
Physical activityWalks 30 to 45 minutes most mornings; light resistance exercises twice a week added for bone health
NutritionRegular balanced meals; dairy and leafy greens for calcium; weight up 0.6 kg since starting androgen deprivation
SleepSeven hours a night; hot flashes wake him about once a week
Activities of daily livingIndependent
Instrumental activities of daily livingIndependent; his assistant manages his calendar and he manages his own medicines
Home safetySmoke detectors working; handrails on the stairs; good lighting
FallsNo falls this year; no fear of falling
Hearing and visionSome difficulty hearing in crowded rooms; wears glasses; eye examination five months ago
MemoryNo concerns
PainOccasional knee stiffness in the morning

Review of Systems

SystemResultFinding
ConstitutionalPositiveSlightly lower energy in the afternoons on androgen deprivation; weight up 0.6 kg; no fever or night sweats
EyesNegativeNo change in vision
Ears, nose, mouth, and throatPositiveSome difficulty hearing in noisy rooms
CardiovascularNegativeNo chest pain, palpitations, or leg swelling
RespiratoryNegativeNo cough, breathlessness, or sputum
GastrointestinalNegativeBowels regular, about once a day, formed; no bleeding
GenitourinaryPositiveMild urinary frequency, unchanged; no blood in the urine
MusculoskeletalPositiveMild morning knee stiffness; no bone pain
IntegumentaryNegativeNo new skin lesions
NeurologicalNegativeNo headache, weakness, or numbness
PsychiatricNegativeMood good; PHQ-2 score 0; no change in memory or concentration
EndocrinePositiveMild hot flashes three or four times a week on androgen deprivation; no breast tenderness

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2001-04-14 to 2001-05-12completedS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapyOne injection every twelve weeks, two dosesIntramuscular route2001-04-21 to 2001-10-06completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2001-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2001-06-09Body height183cmS
2001-06-09Body weight81kgS
2001-06-09Body mass index (BMI) [Ratio]24.2kg/m2S
2001-06-09Systolic blood pressure132mm[Hg]S
2001-06-09Diastolic blood pressure76mm[Hg]S
2001-06-09Heart rate68/minS
2001-06-09Respiratory rate14/minS
2001-06-09Body temperature36.6CelS
2001-06-09Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-06-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2001-06-09Total score [Mini-Cog]5{score}S
2001-06-09Total score [AUDIT-C]0{score}S

Physical Exam

Vital signs recorded on 2001-06-09; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell, alert, and upright; weight 81.0 kg, BMI 24.2
EyesPupils equal and reactive; near vision 20/30 with glasses
EarsCanals clear; whispered-voice test missed on the left, passed on the right
NeckNo thyroid enlargement; no lymph nodes
CardiovascularRegular rhythm at 68 per minute; no murmur; no ankle swelling
RespiratoryClear to auscultation bilaterally
ChestNo gynecomastia or breast tenderness
AbdomenSoft and non-tender
MusculoskeletalMild crepitus in both knees without effusion; Timed Up and Go 10 seconds; rises from a chair without using his arms
NeurologicalAlert and oriented; gait steady; Mini-Cog 5 of 5
PsychiatricEuthymic and engaged; judgment and insight intact
SkinNo suspicious lesions

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Pneumococcal vaccineCompleted todayPCV20 given today; no earlier pneumococcal vaccine on record; no further doses needed
Recombinant zoster vaccineCompleted todayDose 1 given today; dose 2 due in two to six months
Influenza vaccineDueHigh-dose vaccine when this season's supply arrives in the autumn
RSV vaccineDueA single dose is recommended at 75 and older; at the pharmacy before the winter
COVID-19 vaccineDueRecommended at his age with this season's vaccine in the autumn
Tetanus, diphtheria, and pertussis boosterUp to dateTdap seven years ago; next dose due in three years
Colorectal cancer screeningNot indicatedScreening from 76 to 85 is selective; discussed, and not recommended for him now, given his age and his current cancer treatment
Bone densityUp to dateDXA eight weeks ago before androgen deprivation: femoral neck T-score -1.4, spine -0.6; repeat in one to two years
Cholesterol and statin decisionCompleted todayTotal cholesterol 184, HDL 52, LDL 112 mg/dL at the first visit; no diabetes or smoking. Risk calculators are not validated beyond 79, and evidence for starting a statin for primary prevention after 75 is limited; androgen deprivation adds some cardiometabolic risk. Not started after discussion; lipids and glucose again in one year on the androgen deprivation schedule
Lung cancer and abdominal aortic aneurysm screeningNot indicatedNever used tobacco
Hepatitis C and HIV screeningNot indicatedOutside the recommended age ranges and no risk factors
Depression screeningCompleted todayPHQ-2 score 0
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 0
Cognitive assessmentCompleted todayMini-Cog 5 of 5
Falls preventionCompleted todayTimed Up and Go 10 seconds; no falls; walking and resistance exercise continue
HearingReferredWhispered-voice test missed on the left; audiology arranged
Eye examinationUp to dateFive months ago

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Chronic-care follow-up in five weeks with the second leuprolide injection. Radiotherapy to start in about six weeks. Second zoster dose in two to six months. Audiology. Next annual wellness visit in one year. Next scheduled visit 2001-07-14: three-month follow-up on androgen deprivation before radiotherapy: PSA, testosterone, vitamin D, and side effects. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being told the truth about his health, continuing his work for as long as he can, and making his own decisions. He chose not to record specific treatment preferences today. The plan will be revisited yearly and with any change in his health. [S]